Potential number of human cases of H5N1 avian influenza in Egypt

Public Health
W-C TsengL-H Liang

Abstract

H5N1 is one of the avian influenza virus subtypes that has the potential to evolve into a global pandemic that could cause millions of human deaths and great economic losses. Cases involving humans have occurred in 15 countries. Costly interventions have been used by governments and health organisations. Thus, a challenging question arises regarding how many cases of the disease may actually have been prevented as a result of such interventions. This paper answers such a question by applying a statistical model to the 2006-January 2009 outbreak in Egypt. Egypt was chosen as it had the highest number of human avian influenza cases outside Asia, and the second highest number in that period worldwide. Brookmeyer and Blades' statistical model was applied. The sensitivities of the estimated number of human cases and exposure dates to the assumed incubation period, the delay in intervention and the coverage/effectiveness of the intervention were investigated. In the absence of intervention, it appears that the outbreak could have been approximately 1.5 times as large, but it is unlikely it would have exceeded 150 cases. The results underscore the importance of early detection of an outbreak and intervention, together with effective p...Continue Reading

References

Feb 27, 2004·The New England Journal of Medicine·Tinh Hien TranUNKNOWN World Health Organization International Avian Influenza Investigative Team
Aug 5, 2005·Nature·Neil M FergusonDonald S Burke
Nov 25, 2006·The New England Journal of Medicine·Ahmet Faik OnerMehmet Ceyhan
Jan 27, 2007·Science·Dennis Normile, Martin Enserink
Aug 22, 2007·Lancet·May Meleigy
Sep 4, 2007·American Journal of Infection Control·Ji-Ming ChenYing-Xue Sun
Jan 18, 2008·The New England Journal of Medicine·UNKNOWN Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian InfTimothy M Uyeki
Jan 25, 2008·Emerging Infectious Diseases·Magdi D SaadMarshall R Montevillel
Mar 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Marius GilbertJan Slingenbergh
Apr 18, 2008·Agriculture, Ecosystems & Environment·Marius GilbertJan Slingenbergh
May 15, 2008·Journal of Epidemiology and Community Health·F C K LiA W P Pak
Nov 4, 2008·Emerging Infectious Diseases·Yang HuaiHongjie Yu
May 9, 2009·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·J P Dudley
Dec 25, 2009·Emerging Infectious Diseases·Alan Schroedl
Jan 1, 2009·Journal of Infection and Public Health·Kenneth C EarhartJeffrey A Tjaden
Oct 1, 2008·Tourism Management·Hsiao-I KuoBing-Wen Huang

❮ Previous
Next ❯

Citations

Aug 27, 2013·PloS One·Whitney S KruegerGregory C Gray
May 20, 2017·EcoHealth·Kate A HarrisUNKNOWN FLURISK Consortium
May 4, 2010·Journal of Medical Systems·Elcin YoldascanEsra Koyuncu
Oct 22, 2009·Luminescence : the Journal of Biological and Chemical Luminescence·Liping ChenMeilin Jin
Oct 20, 2009·Der Nervenarzt·M LöbermannU K Zettl
Mar 20, 2010·Microbiology and Immunology·Emi InoueKatsunori Okazaki
Nov 27, 2009·Biotechnology Letters·Qing-long LiangHong-xuan He
Jan 14, 2010·Archives of Virology·Maricela Montalvo-Corral, Jesús Hernández
Nov 13, 2018·Risk Analysis : an Official Publication of the Society for Risk Analysis·Gregory LewisGigi Gronvall
Jan 28, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·A R Zanetti, A Zappa
Dec 25, 2009·Current Microbiology·E FrobertO Ferraris
Apr 23, 2010·Influenza and Other Respiratory Viruses·J Jeremy SuekerUNKNOWN DoD Influenza Working Group
Mar 26, 2010·Journal of Medical Virology·Guillermo Ruiz-CarrascosoPilar Pérez-Breña
Apr 13, 2010·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Dong Han LeeJong Koo Lee
Mar 25, 2011·Environmental Health and Preventive Medicine·Hiroyuki FuruyaTetsu Watanabe
Sep 6, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vuong N BuiGregory C Gray
Oct 7, 2018·Archives of Virology·Mi-Seon LeeHwajung Yi
Feb 12, 2019·Archives of Virology·Ainur NurpeisovaBerik Khairullin
Mar 18, 2019·Communicable Diseases Intelligence·UNKNOWN NNDSS Annual Report Working Group
May 22, 2018·Epidemiology and Infection·Rokshana ParvinThomas W Vahlenkamp
Jun 1, 2010·Nature Biotechnology·Richard Y KaoKwok-Yung Yuen
Jun 9, 2016·Epidemiology and Infection·A BethmontC R Macintyre
Jul 25, 2015·Epidemiology and Infection·W D TannerA V Gundlapalli
Oct 13, 2010·Nature Reviews. Microbiology·Kim M PepinJames O Lloyd-Smith
Sep 6, 2011·Prehospital and Disaster Medicine·Karen P PhillipsCarol A Amaratunga
Jul 2, 2010·Animal Health Research Reviews·Hadi M YassineYehia M Saif
Jul 2, 2010·Animal Health Research Reviews·Heather L Forrest, Robert G Webster
Jul 2, 2010·Animal Health Research Reviews·Daniel A JaniesJonathon Studer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

Emerging Infectious Diseases
R G WebsterY Guan
Proceedings of the National Academy of Sciences of the United States of America
G J D SmithY Guan
© 2021 Meta ULC. All rights reserved